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A subpopulation ofperipheral blood Tlymphocytes express anovelnon-a, non-0
Tcell receptor (TCR) heterodimer that is associated with the CD3 complex. This
heterodimer is composed ofTCRy and TCRS polypeptides which aredistinct from
each other on the basis of immunochemical criteria (1-3) and by peptide mapping
(4), and are encoded by different genes.
The TCRy (5, 6) and TCRS (7-9) genes are composed ofvariable (V), joining
(J), and constant (C) region segments that undergo somatic rearrangement in T
cells (7, 10, 11), as isthe case forTCRa, TCRa, and Ig genes. In thehuman germ-
line, six or seven functional TCRy variable gene segments have been identified
(12-14) that are located 5' of two constant region gene segments, designated Cyl
and Cy2 (15). The TCRy constant gene segments consist of three exons, namely
the CI exon (encoding an extracellular, Ig-like constant domain), a short CII exon
(encoding a connectingpeptide), and theCIII exon (encodingthe membrane span-
ning region and a short intracellular tail).
In man, two protein forms of the TCR-y/8 have been well described. The first
form is composed of 40 kD TCR-y polypeptides, associated by a disulfide bridge
with a TCRS protein (16-18). In contrast, the other form consists ofa 55 kD TCR-
y protein that is noncovalently associated with a TCR-S polypeptide (1, 17, 19).
cDNA clones representing the transcripts for thedisulfide-linked TCRy polypep-
tide on T cell clone PBL-Cl demonstrated that its constant region is encoded by
theCyl gene segment (4). The single CII exon in Cyl encodes an extracellular, un-
paired cysteine that isimplicated in disulfide linkage withthe TCRS subunit. cDNA
clones encoding the 55-kD non-disulfide-linked TCRy have been analyzed from
the IDP2 and PEER cell lines (4, 20). They use the Cy2 gene segment and reveal
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the presence of three CII exons (CII exon copy a, b, and c). Interestingly, although
the three CII exons of the Cy2 gene show a high degree of sequence identity with
the Cyl counterpart, each of the three copies of the Cy2 CII exons is unique. The
cysteine present in the single Cyl CII exon is replaced with another amino acid
in all three Cy2 CII exon copies. Moreover, CII exon copies b and c each bear poten-
tial N-linked glycan attachment sites, accounting for the larger size of the non-disulfide-
linked Cy2 (55 kD) versus the disulfide-linked Cyl (40 kD) polypeptide subunits.
Besides these TCRy/S types, an additional form characterized by a 40-kD, non-
disulfide-linked TCR-y chain exists (9, 17). It contains structural features that could
not be accounted for by the known Cyl (40-kD, disulfide-linked polypeptide) or the
known Cy2 (55-kD, non-disulfide-linked polypeptide) gene segments. This third form
is not disulfide linked to its partner (similar to Cy2) but reveals a short (40-kD) poly-
peptide (similar to Cyl). In the present study, we characterize this third TCR-Y/6
protein structure and compare it with the two other forms. We present the primary
structure of this TCRy form determined through cDNA sequence analysis and pro-
pose an explanation for the observed cell surface protein structure.
Materials and Methods
Antibodies.
￿
mAbs used were anti-Leu-4 (anti-CD3) (21), PFl (antiTCRa) (22), antiTCR
S1 (antiTCR-S) (3), P3 (control) (secreted by P3X63Ag8) (23), 187.1 (rat anti-mouse x light
chain) (24), and WT31 (stains TCRa/a lymphocytes brightly) (25). Anti-Cyb peptide serum
(antiTCRy) generated against a 22-amino acid synthetic peptide (Gln-Leu-Asp-Ala-Asp-
Val-Ser-Pro-Lys-ProThr-Ile-Phe-Leu-Pro-Ser-Ile-Ala-Glu Thr-Lys-Cys) was generously pro-
vided by T Cell Sciences Inc., Cambridge, MA.
Cell Lines.
￿
PEER (19) and MOLT-13 (isolated by J . Minowada, Fujisaki Cell Center,
Okayama, Japan) (9) are T leukemic cell lines. Umbilical cord blood-derived clone WM-14
(26), peripheral blood-derived cell line IDP2 (1) and thymus-derived Clone II (27) were cul-
tured as described earlier. Peripheral blood-derived cell line 2 (PBL-L2) was isolated by sorting
peripheral blood-isolated lymphocytes that did not stain with mAb WT31 . The isolated cells
were then expanded in vitro in RPMI 1640 medium supplemented with 10% (vol/vol) condi-
tioned medium containing IL-2 and 10% (vol/vol) human serum, and stimulated every 3
wk with irradiated autologous feeder cells.
Iodination and Immunoprecipitation .
￿
2 x 10' cells were isolated by Ficoll-diatrizoate (Or-
ganon Teknika Corp., Durham, NC) centrifugation and iodinated on ice as described before
(1) . Cells were solubilized overnight in detergent supplemented TBS' (50 mM Tris-Base, pH
7 .6, 140 mM NaCl) containing 1 mM PMSF and 8 mM iodoacetamide (IAA). As indicated,
different detergents used in this study were 0.35o (wt/vol) 3-[(3-cholamidopropyl) dimethylam-
monio] 1-propane-sulfonate (CHAPS), 1% (wt/vol) digitonin, and Triton X-100 (TX-100).
After 20 min of centrifugation at 10,000 g to remove insoluble material, detergent lysates
were precleared by a 30-min incubation with 4 wl of normal rabbit serum (NRS) and 400
ul of 187.1 hybridoma culture medium, followed by addition of 200 wl of a 10% (wt/vol) cell
suspension offixed Staphylococcus aureus Cowan I (PANSORBIN; Calbiochem-Behring Corp.,
San Diego, CA). After a 1-h incubation Pansorbin was removed by centrifugation. Specific
precipitations were carried out by adding 0.25 wl (3F1 ascites, 1 Id anti-Leu-4 (1 mg/ml) or
0.25 wl P3 ascites, together with 150 gl of 187.1 culture supernatant to each sample, followed
by a 1-h incubation. The efficiency of RFl-immunoprecipitation was improved by the addi-
tion of TX-100 detergent to a finalconcentration of 1% (vol/vol). 100 wl of 10% (vol/vol) pro-
tein A-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) was added and the mixture
was rocked for 1 h at 4°C. Immunoprecipitates were washed five times with 0.1% (vol/vol)
Abbreviation used in this paper: TBS, Tris-buffered saline.HOCHSTENBACH ET AL.
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TX-100 containing TBS and analyzed by SDS-PAGE (28). Immunoprecipitations with the
anti-Cyb peptide serum were performed as described before (3).
Biosynthetic Labeling.
￿
4 x 10' exponentially growing cells were resuspended in 4 ml of
methionine-and cysteine-free RPMI 1640 (Select-Amine kit; Gibco Laboratories, Grand Is-
land, NY) supplemented with 1017o dialyzed FCS and 20 mM Hepes, pH 7 .4. After a 30-min
starvation period at 37°C, 1 MCi of [s5S]methionine and 1 MCi of [35S]cysteine were added,
allowing a 15-min labeling period. Cells were harvested and solubilized in 2 % (vol/vol) TX-
100, TBS. Preclearing and immunoprecipitations were performed as described above. The
immunoprecipitates were washed four times in 0.5% (vol/vol) TX-100, 0.5% (wt/vol) deoxy-
cholic acid, 0.05% (wt/vol) SDS, TBS followed by three washes in 0.5% (vol/vol) TX-100,
0.5 M NaCl, 5 mM EDTA, 50 mM Tris, pH 7.6. The samples separated in SDS-PAGE and
visualized by standard fluorography procedures (29).
Gel Purification of -CC-6 Proteins.
￿
Surface-iodinated cells were solubilized in 0.3 ,70 (wt/vol)
CHAPSTBS and immunoprecipitated using 50 pl of anti-Leu-4-coupled Sepharose beads.
The immunoprecipitated species were resolved by SDS-PAGE under nonreducing conditions
and the wet gel was exposed for 24 h at 4'C on XAR5 film (Eastman Kodak Co., Rochester,
NY) to visualize radiolabeled TCR8 proteins. The gel regions corresponding to TCRS were
excised, incubated in 5% (vol/vol) 2-ME containing sample buffer, and resolved a second
time by SDS-PAGE. Because of the characteristic SDS-PAGE mobility shiftupon reduction,
TCRS protein could be separated from contaminants. TCR proteins were eluted from gel
slices by overnight incubation in 0.05 17c (wt/vol) SDS, 50 mM ammonium bicarbonate buffer
at 37 0C and were lyophilized.
Endoglycosidase Digestion.
￿
For endoglycosidase H digestions, immunoprecipitated mate-
rial or gel purified protein was boiled for 3 min in a 40 pl 1 % (wt/vol) SDS solution con-
taining 0.14 M 2-ME. After cooling, the mixture was diluted with 360 pl of 0.15 M acetate
buffer, pH 5.5, containing 1 mM PMSE 5 pl Endo H (1 U/ml; Endo-R-N-acetyl-
glucosaminidase H; Genzyme, Boston, MA) was incubated with half of the above solution
for 16 h at 37'C, while the other half was mock incubated.
For N-glycanase digestion, gel-purified material was boiled for 3 min in 35 pl of0.5 % (wt/vol)
SDS, 0.10 M 2-ME. Then, 100 pl of 0.2 M sodium phosphate (pH 8.6),1.25% (vol/vol) TX-
100 was added. Halfof the mixture was incubated with 1 pl N-glycanase (250 U/ml, peptide-
N-[N-acetyl-P-glucosaminyl]asparagine amidase; Genzyme) and incubated for 16 h at 37°C,
while the other half was mock treated.
After digestion, 10 pg BSA was added as carrier and samples were recovered by TCA precipi-
tation. Protein pellets were taken up in sample buffer containing 5% (vol/vol) 2-ME.
Production ofmAb Anti-CyMl. Part of the Cy CI and CII exons of HPB-MLT pTy-1 was
isolated using the Barn HI and Pst I sites at nucleotide positions 571 and 848 (30) and was
cloned into expression vector pRIT2T (Pharmacia Fine Chemicals). The resulting protein
A-fusion protein was expressed in Escherichia coli N4830. Bacteria were lysed with lysozyme
and the fusion protein was isolated by purification over an IgG Sepharose column. Mice were
injected intraperitoneally with 100 pg of fusion protein in Freund's adjuvant at days 0, 7,
and 28. 28 d later 100 gg offusion protein in PBS was injected intravenously After 3 d spleno-
cytes were isolated and fused with the myeloma P3X63Ag8.653 as described (22) . Hybrid-
omas were screened by ELISA. 96-well flat-bottomed plates (Linbro; Flow Laboratories Inc.,
McLean, VA) were incubated overnight with 0 .4 pg of fusion protein or nonfused protein
in PBS. Nonspecific binding sites were blocked at 23'C with 0.25 mg/ml normal rabbit IgG
(Sigma Chemical Co., St. Louis, MO) in PBS containing 50% (vol/vol) FCS. 50 pl of hy-
bridoma supernatant was added for 1 h at 4°C, followed by a similar incubation in 50 pl
of a 5 pg/ml solution of peroxidase-conjugated anti-mouse IgG (Cappel Laboratories,
Cochranville, PA). All described incubations were interspersed with washing steps, using 10%
(vol/vol) FCS, 0.1% (wt/vol) BSA, PBS. The ELISA was developed with 0.08% (wt/vol) O-
phenylene diamine in 0.012 % (wt/vol) hydrogen peroxide containing phosphate-citrate buffer,
pH 5.0. Hybridoma number three, secreting anti-CyM1 mAb, was selected for further study.
Although anti-CyMI does not recognize the native TCRy/S/CD3 complex in cytofluoro-
graphic analysis nor the TCRy/S heterodimer from TX-100 solubilized cells in immunopre-
cipitation (data not shown), it does recognize biosynthetically labeled TCRy precursor, as764
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well as mature TCR-y proteins after separation of CD3/TCRy/S proteins into individual
chains. After separation CD3/TCRy/S complexes into individual chains by boiling in 1%
(wt/vol) SDS, anti-CyM1 was shown to specifically recognize the TCRy protein (Fig. 2 B,
lane 3). Since this mAb was generated against aconstant region-encoded peptide, and reacts
with both Cyl- and Cy2-encoded TCRy chains, it is likely to possess framework reactivity
against all TCR-y polypeptides (unpublished observations).
Isolation and Sequencing of a MOLT-13 TCR-y cDNA Clone.
￿
Poly(A)' RNA was prepared
from MOLT13 cells by urea/lithium chloride precipitation followed by oligo(dT)-cellulose
affinity chromatography. A %gt10 cDNA library was prepared from poly(A)` RNA by the
method of Huynh et al. (31) using Mung Bean Nuclease (Promega Corp., Madison, WI)
for the hairpin loop cleavage. The cDNA library was amplified on the E. coli strain C600
Hfl and screened by plaque filter hybridization with 32P-labeled pTyl (30). Positive clones
were analyzed forsize and restriction enzyme map, and cDNA clone M13k was selected for
sequencing. The cDNA of M13k was excised from Xgt10 phage with the endonuclease Eco
RI and furtherdigested with appropriate restricting enzymes. Thefragments were subcloned
into M13 vectors and sequenced by the dideoxy chain termination method (32) using the
modified T7 polymerase (Sequenase; United States Biochemical Corp., Cleveland, OH).
CloneM13k corresponds to afull length, in-frame, TCRy transcript, including36 nucleo-
tides of5' untranslated region and 72 nucleotides of 3' noncoding region (Fig. 3). Thenucleo-
tide sequence of the V region is identical to the genomic Vyl.3 sequence (12, 14), except for
a C to T (Ile to Val) change of nucleotide 53 in the putative signal sequence. TheJ region
is identical to theJy2.3 sequence (33, 34). Interestingly, eight nucleotides occur at the VJ
junction that do not appear to be encoded by thegenomic VorJsequences and presumably
comprise an N region. TheC region sequences match the corresponding genomic sequence
(15), with the exception of nucleotide 559 (G to C; Val to Ile) and nucleotide 908 (T to C;
Met to Thr).
Results
Third Form of the TCR-y16.
￿
In an attempt to delineate the non-disulfide-linked
40-kD TCRy form, we produced and characterized a number of cell lines derived
from normal human donors. Peripheral blood lymphocytes were stained with mAb
WT31, whichbrightly stains restingTCRa/P lymphocytes. Cellsthat did not stain
were isolated by cell sorting and then expanded in vitro in IL-2-containing medium.
FIGURE 1.
￿
ThreeformsoftheTCRy/S. The antibodies used forimmunoprecipitation are anti-
Leu-4 (anti-CD3), 0Fl (antiTCR-0), antiTCRS1 (antiTCR-S), anti-Cyb serum (antiTCR-y),
and P3 (unlabeled lanes, control) as shown at the top of each lane, while the "'I-labeled cell
line used is shown at the bottom of each 10% SDS-PAGE autoradiograph. R indicates that the
immunoprecipitate was resolved under reducing conditions and Nindicates that nonreducing
conditions were used. M, (10-3)markers are shown to theleft. An open arrow indicates the po-
sition of TCR8 under reducing conditions, whereas the closed arrow denotes the position of
TCRS undernonreducing conditions. (A)Non-disulfide-linked TCR-y(40 kD)on PBL-L2. In
lanes 1-6the radiolabeled cellswere solubilized in 0.3% CHAPS detergentwhich preserves the
TCRCD3 association, whereasin lanes 7and8, immunoprecipitates were performedafterchain
separation (see Materials and Methods). Note that the arrows point to TCRS positions under
reducing and nonreducing conditions. (B) Non-disulfide-linked TCRy (55 kD)on IDP2 cells.
In lanes 1-4 radiolabeled cells were solubilized in 0.3% CHAPS detergent, whereas in lanes 5
and 6 immunoprecipitates were carried out afterchain separation. (C) Disulfide-linked TCRy
(40kD)on WM-14 cells. Alllanescorrespond to immunoprecipitations from 1% digitonin solu-
bilized radiolabeled cells. (D) Non-disulfide-linked TCRy (40 kD) on thymic Clone II cells. Ra-
diolabeled cells were solubilized in 1% digitonin(lanes 1-4) or in 0.1% TX-100 (lanes 5 and 6),
whereas in lanes 7 and 8 immunoprecipitations were carried out after chain separation. (E)
Non-disulfide-linked TCRy (40kD) on MOLT-13Tleukemia cells. In lanes 1-4 immunoprecipi-
tationswere carried outaftersolubilization of cells in 0.3% CHAPS detergent, whereas in lanes
5 and 6 immunoprecipitations were carried out after chain separation.HOCHSTENBACH ET AL .
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Peripheral blood lymphocyte line 2 (PBL-L2) obtained in this way proved to be
homogeneously CD3+CD4-CD8- (data not shown), a cell surface phenotype typ-
ical of TCR-y/8 lymphocytes.
To visualize TCR-y/6 complexes onPBL-L2 cells, immunoprecipitations with an
anti-CD3 mAb were carried out from cell surface "'I-labeled cells solubilized in
CHAPS ordigitonin. In these detergents, the physical association between theCD3
complex and TCR-y/8 subunits is preserved. SDS-PAGE of anti-CD3 im-
munoprecipitates from PBL-L2 cells resolved 40-kD and 44-kD proteins (referred
to as 40 kD) that were identified as TCR-f subunits by anti-Cybserum, an antiserum
directed against a TCRy constant region peptide (Fig. 1 A; see Materials and
Methods section).
These TCR-,y proteins on PBL-L2 are noncovalently associated with a TCR-8
subunit, which isvisible as a weakly iodinatedprotein intheanti-CD3 immunoprecipi-
tation analyzed under nonreducing conditions (Fig. 1 A, lane 6, closed arrow). This
weakly iodinated protein represents the TCR-8 subunit on PBL-L2 cells, since it
is not recognized by anti-Cyb serum (Fig. 1 A, lane 8). In addition, it displays the
same SDS-PAGE mobility shift comparing analysisunder nonreducing and reducing
conditions as was noted forthe TCR-8 proteins on IDP2 and PEER cells (see below)
(17). The TCRS protein could not be visualized after reduction (Fig. 1 A, lane 3),
because it migrated with a mobility of 40 kD (see below) and then was obscured
by the similar sized TCR-,y protein (open arrow).
This TCRy/8 form is not only present on normal peripheral blood T lympho-
cytes, but is also observed on thymus-derived Clone II cells (Fig. 1 D) (27), and
on the T-leukemic cell line MOLT13 (Fig. 1 E) (9). These three cell lines possess
TCR-,y species that display differential glycosylation resulting in a TCR-y protein
doublet observed on PBL-L2 (40 kD and 44 kD; Fig. 1 A, lane 8) and Clone II
cells (40kD and 44kD; Fig. 1 D, lane 8) or a diffusely labeled TCRy protein band
observed on MOLT-13 cells (40-46 kD; Fig. 1 E, lane 6). Two-dimensional gel anal-
ysis (nonequilibrium pH gradient electrophoresis [NEPHGE] followed by SDS-PAGE)
of the MOLT-13 TCR-,y protein band resolved two TCR-,y species (40 kD and 44
kD), ofwhich the 44-kD TCR-y species contained an additional high mannose (or
hybrid) N-linked glycan compared with the 40-kD TCRy species (data not shown).
We conclude that the TCRy subunits ofthis receptor complex isolated from three
different cell sources (peripheral blood, thymus, and a leukemia) reveal cell surface
species of 40 kD that are noncovalently associated with TCRS partner chains.
For comparison to the TCR-y/8 form on PBL-L2, Clone II, and MOLT-13 cells,
we examined the previously characterized forms on the IDP2 and WM-14 cell lines.
The IDP2 cell line (1) contains a larger, 55-kD TCRy protein, that is recognized
by anti-Cyb serum (Fig. 1 B). When the anti-CD3 immunoprecipitate is examined
under nonreducingconditions, it is evident that the IDP2 TCR-,y protein is associated
noncovalently with its TCR-8 partner chain (Fig. 1 B, lane 4, closed arrow). Upon
reduction, the TCR-8 protein displays a decrease in SDS-PAGE mobility to a rela-
tive molecular mass of 40 kD (compare Fig. 1 B, lane 4, closed arrow, with Fig. 1
B, lane 2, open arrow).
In contrast to the noncovalently associated TCRy/8 forms, the umbilical cord
blood-derived T cell clone, WM-14, bears a disulfide-linked TCR dimer of 70 kD
(Fig. 1 C, lane 7, closed arrow), which was recognized by anti-Cy serum (26). ThisHOCHSTENBACH ET AL.
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FIGURE 2 .
￿
Peptide backbone sizes of TCR-y from PEER and MOLT-13 cells . mAbs used for
immunoprecipitation are anti-Leu-4 (anti-CD3), anti-CyMl (antiTCR y), antiTCR61 (anti-
TCR-6), and P3 (unlabeled lane, control) as shown at the top ofeach lane . The labeled cell lines
used are shown at the bottom ofeach 10% SDS-PAGE autoradiograph or fluorograph . All samples
were resolved under reducing conditions . M, (10-3 ) markers are indicated to the left . (A) Pep-
tide backbone sizes of TCRy from PEER and MOLT-13 cells . Cells were biosynthetically la-
beled with [
31S]cysteine and [ 35S]methionine for 15 min . Samples were either treated with Endo
H (+) or mock treated (-) . Immunoprecipitation with anti-CYMl shows the positions of imma-
ture TCRy ofPEER cells (lane 3) and ofMOLT13 cells (lane 7), while the corresponding poly-
peptide backbone sizes are visualized after treatment with endoH (lanes 4 and 8) . (B) Specificity
ofanti-CyMI mAb. Cell surface-radiolabeled cells were solubilized in 0.3% CHAPS detergent
and the TCRy/8-CD3 complex was isolated with anti-CD3 mAb (lane 1) . Anti-CyM1 specifically
immunoprecipitates the TCR-y subunit (lane 3) after separating the chains of the isolated TCR
y/6-CD3 complexes, compared with antiTCR61 which specifically immunoprecipitates theTCR
6 chain (lane 4). (C) Glycosylation of TCR-6 from MOLT-13 cells . 1251-labeled cells were im-
munoprecipitated with anti-CD3 mAb and the TCR6 polypeptides were gel purified (see
Materials and Methods) . Samples were treated with Endo H (lane 2) or with N-glycanase (lane
4), or mock treated (lanes 1 and 3). The decrease of 2.5 x 10 3 inM r after endo H digestion (lane
2) indicates the presence of one high mannose or hybrid N-linked glycan on the TCR-6 chain .
A further 2.5 x 10 3 decrease in M, followed digestion with N-glycanase (lane 4).
dimer is also recognized by antiTCRS1 (3), a mAb directed against the TCRS
subunit (Fig . 1 C, lane 5), and therefore represents aTCRy/S heterodimer. Anal-
ysis under reducing conditions reveals TCRy proteins of40 kD and 36 kD (referred
to as 40 kD) and a43-kDTCR6 protein (Fig . 1 C, lane 8, open arrow) . These subunits
were identified by recognition with anti-Cyb serumand by two-dimensional gel anal-
ysis (data not shown) .
Thus, the CD3-associated complexonPBL-L2, Clone II, andMOLT13 cells con-
stitute aTCRy/S heterodimer that is distinct from, but related to, the otherknown
forms, since itsTCRy subunit is 40 kD (similar in size to thedisulfide-linked, Cyl-768
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encoded TCR-y protein on WM-14 cells), yet it is not disulfide linked to its partner
chain (similar to the 55-kD, Cy2-encoded TCR-y protein on IDP2 cells). To under-
stand the molecular basis of this complex a more detailed structural analysis of its
TCR-y and TCR-8 subunits was carried out, using the MOLT-13 cell line as an
example.
Core Pblypeabtide Size ofMOLT13 TCR-y Subunit.
￿
To determine the size ofthe TCR-y
core polypeptide ofMOLT-13 cells (40-kD TCRy glycoprotein), and compare it with
that of PEER cells (55-kD TCR-y glycoprotein), both cell lines were biosyntheti-
cally labeled for 15 min in the presence of [35S]methionine and ["S]cysteine, solu-
bilized in Triton X-100 and then immunoprecipitated with anti-CyMI, a new mAb
that specifically recognizes theTCRy chain (Fig. 2 B, see Materials and Methods).
Immunoprecipitated material wasdigested with endoglycosidase H(Endo H) to re-
move the immature N-linked glycans. The MOLT13 TCR-y polypeptide backbone
has a relative molecular mass of 35 kD (Fig. 2 A, lane 8), which is 5 kD smaller
than the PEER TCRy core polypeptide (40 kD; Fig. 2A, lane 4)or the IDP2 TCR-y
core polypeptide (40 kD) (17). This 5-kD difference in polypeptide core size cannot
solely account for the 15-kD difference in size between the MOLT13 (40 kD) and
PEER (55 kD) cell surface proteins. The remaining 10-kD difference in size must
result from differences in posttranslational processing between two TCR-y chains.
While 15-20 kD of relative molecular mass can be accounted for by posttransla-
tional processes on the PEER and IDP2 TCR-y glycoproteins (55-60 kD surface
size minus 40-kD core size), only 5-11 kD ofsize on the mature MOLT-13 TCR-y
glycoprotein is accounted for by posttranslational processes (40-46-kD surface size
minus 35-kD core size). Experiments using tunicamycin to inhibit the addition of
N-linked carbohydratesto the polypeptide chain confirmed that the posttranslational
processing is largely, ifnot totally accounted for, by the addition ofN-linked glycans
(data not shown). Assuming that each glycan accounts for ti3 kD ofrelative molec-
ular mass, we predict that two or three N-linked glycans are attached to the MOLT
13 TCR-y protein, while five N-linked glycans are added to the TCR-y polypeptides
on PEER and IDP2 cells.
Primary Sequence ofMOLT-13 TU'R-y.
￿
To understand the structure ofthe constant
region gene segment encoding the MOLT-13 TCR-y subunit, the sequenceofacDNA
clone representing the MOLT-13 TCRy transcript was determined. A ?,gt10 library
from MOLT-13-derived poly (A)+ RNA was constructed and probed with a human
TCR-ycDNA clone, pTy-1 (30). Based on size and limited restriction enzyme map-
ping one clone, M13k, was selected and its nucleotide sequence was determined (Fig.
3). Clone M13k represents a full length, in-frame TCR-y transcript, using a Vy1.3
gene segmentjoined to ajy2.3 gene segment (12, 33; nomenclature based on refer-
ences 14, 34). The constant region sequence was found to be encoded by two CH
exons, copies b and c, similar to a recently reported nonfunctional TCR-r (36) and
to the Cy2 genomic sequence containing two CII exons (15).
Thededucedamino acid sequence ofthis cDNA clonepredicts a polypeptideback-
bone size of34.8 kD, which is in good agreement with biochemical data described
above. Surprisingly, six potential N-linked carbohydrate attachment sites are encoded
by this transcript . Since the biochemical dataindicatethatonlytwo orthreeN-linked
glycans are attached to the polypeptide chain, we predict that most ofthe potential
glycan acceptor sites are not used.HOCHSTENBACH ET AL .
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FIGURE 3 .
￿
Nucleotide sequence ofMOLT13 TCRy. (A) Sequencing strategy of clone M13k .
A partial restrictionmap of the 1.1-kb cDNA cloneM13k is shown . (B) Nucleotide anddeduced
amino acid sequence of clone M13k . Signal sequence (S), variable (V), N region (N), joining
(J), and constant (CI, CIIb, CIIc, and CIII) region gene segments are indicated by arrows and
were identified by comparison to genomic sequences (for S andV : 12, 14 ; forJ : 33, 34; for C:
15, 36). The deduced amino acid sequence beginning at the initiator methionine is presented
below the nucleotide sequence, using single-letter codes . Extracellular cysteines are highlighted
by boxes, and potential N-linked carbohydrate attachment sites(N-X-S or N-XT) (35) are indi-
cated by brackets . These sequence data have been submittedto theEMBL/GenBankData Libraries
under accession number Y00790 .
To reflect Cy gene segment usage for purpose of nomenclature, we have denoted
the disulfide-linked TCRy/S form expressed by PBL-Cl and WM-14 as "form 1,"
since such disulfide-linked TCR-y chains use the Cyl gene segment . The large (55
kD), non-disulfide-linked TCRy subunit of the TCRy/S form expressed on IDP2
andPEER cells is encoded by Cy2 gene segments containing three CII exons (copies
a, b, and c) andtherefore this TCR-y/8 form will be called "form 2abc ." Correspond-770
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FIGURE 4 . Unequal use of TCR-y/8
forms. Freshly isolated peripheral blood
mononuclear cells from healthy donors
were "'I-labeled and solubilized in 1%
Triton X-100 . Immunoprecipitates with P3
control antibody (lanes 1 and 3) and anti-
TCRS1 (lanes 2 and 4) were analyzed
under nonreducing(N; lanes 1 and 2) and
reducing (R ; lanes 3 and 4) conditions .
M, (x 10-3 ) markers are shown on the
left .
ingly, the form on MOLT13 cells using two CII exons (copies b and c) will be re-
ferred to as "form 2bc."
Unequal Cy Gene Segment Usage .
￿
To determine the presence of these three TCR-
y/S forms in freshly isolated peripheral blood we analyzed the mononuclear cells
from 10 healthy subjects using biochemical analysis with mAb antiTCRS1 . This
reagent appears to react with all TCRy/S lymphocytes (3, our unpublished obser-
vations) . Representative results from this panel are shown in Fig . 4. In subject 1,
antiTCRS1 immunoprecipitates (analyzed under nonreducing conditions) demon-
strate the presence of both disulfide-linked TCR-y/8 complexes as a 70-kD protein
band (form 1) and non-disulfide-linked TCR-y/8 complexes as a broad 40-kD pro-
tein band (form 2bc) (Fig. 4, lane 2) . This indicates that the Cyl and Cy2 constant
regions are both used by the expressed y/ST cell receptors of this individual. How-
ever, the amount of form 2bc varied among individuals . Note the smaller fraction
of form 2bc in subject 2 compared with subject 1 by comparing the intensity of the
40-kD protein bands in both individuals (compare lane 2 of subject 2 with lane 2
of subject 1) . Even more strikingly, only disulfide-linked TCR-Y/8 complexes could
be detected on the mononuclear cells of3 ofthe 10 individuals examined, even after
long exposure ofthe autoradiographs (see subject 3) . None of the analyzed individ-
uals revealed the 55-kD, non-disulfide-linked TCR-y/8 complex (form 2abc) in pe-
ripheral blood .
Glycosylation ofthe TCR-S Subunit.
￿
In contrast to the striking structural differences
in size and glycosylation of the TCR-y proteins, the TCR-S subunits from differentHOCHSTENBACH ET AL .
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cell sourceswere remarkably similar. The relative molecular mass of theTCR8 gly-
coprotein on MOLT13 cells was directly determined to be 40 kD using the anti-
TCR-S mAb (Fig. 2 B, lane 4), confirming that it is similar in size to the TCR-S
glycoprotein on IDP2 cells (Fig . 1 B, lane 2, open arrow) .
To also determine its polypeptide backbone size, cell surface "'I-labeled TCRS
protein ofMOLT-13 wasdigested with N-glycanase to remove asparagine-linked glycans
(of the high mannose, hybrid, and complex type) (37, 38) . The TCR8 core poly-
peptide ofMOLT13 cells has a relative molecular mass of 35 kD (Fig . 2 C, lane
4), which is similar to that ofthe TCRS backbone ofIDP2 cells (35 kD) (3) . Diges-
tion with endoglycosidase H (Endo H, removing only high mannose and certain
hybrid N-glycans) (39, 40) caused a decrease in relative molecular mass of 2.5 kD
(Fig . 2 C, lane 2), consistent with the presence of one carbohydrate moiety, leaving
a relative mass of 2.5 kD of Endo H-resistant carbohydrates attached to the poly-
peptide . Since there are two potential N-glycan attachment sites present in theTCRS
constant domain (8, 9), these data directly show that both are used, but that their
N-glycans are differentlyprocessed, namely one as a high mannose N-glycan (Endo
H-sensitive) and the other as a complex N-glycan (Endo H-resistant, but N-
glycanase-sensitive) and the other as a complex N-glycan (Endo H-resistant, but
N-glycanase-sensitive) . In contrast to the different amounts of attached N-linked
carbohydrate on TCRy polypeptide chains, theTCR8 subunits expressed on PEER,
IDP2, and MOLT-13 cells all revealed the same peptide core sizes and the presence
of two N-linked glycans (Fig . 2 C, and data not shown) .772 THIRD FORM OF THE HUMAN T CELL RECEPTOR y/S
Discussion
In this study, three protein formsofthehuman TCRy glycoprotein are compared,
namely the disulfide-linked 40-kD TCR-y(form 1), the non-disulfide-linked 55-kD
TCR-y (form 2abc), and the non-disulfide-linked 40-kD TCRy protein (form 2bc).
All three forms are shown to be associated with a TCR-8 subunit. cDNA sequences
representing the first two TCRy forms have been reported previously (4, 20). The
constant region ofTCR-y form 1 (on PBL-CI) is encoded by the Cyl gene segment
containing a single CII exon, while TCR-y form 2abc (on IDP2 and PEER cells)
uses the Cy2 gene segment containing CII exon copies a, b, and c. The cDNA se-
quence correspondingto a TCRy chain ofform 2bc (on MOLT13 cells, this study)
was shown to contain a Cy2 gene segment usingonly two CII exon copies, namely
copy b and copy c. Similarly, it seems likely that the gene structure ofthe TCRy
connector region ofclone II and PBL-L2 (non-disulfide-linked, 40-kD TCR-y pro-
tein) will also be like the MOLT-13 structure, namely ofform 2bc. Since the TCR8
constant region used is the same in all three forms (8, 9) (Brenner, M. B., and M.
Krangel, unpublished observations) a complete comparison ofthe structures ofthe
three TCRy/8 forms in man can be made (Fig. 5).
The fact that two Cy2 polymorphic genomic forms exist (15, 36) suggests that the
two transcript forms (form 2abc and form. 2bc) are the product of these different
allelic types. Interestingly, the dramatic difference in TCRy cell surface protein size
betweenform2abc (55 kD)andform2bc(40 kD)is largelydeterminedby the amount
ofattached N-linked carbohydrates, most likely reflecting the number ofN-linked
glycans. Backbone sizes of IDP2 TCR-y (form 2abc) and MOLT-13 TCR-y (form
2bc) proteins have been measured to be 40 kD and 35 kD, respectively, on the basis
of SDS-PAGE, which correlates well with their predicted molecular masses of36.6
and 34.8 kD, respectively, calculated on the basis of cDNA sequences. It is clear
thatthis smalldifference in backbone size(5 kD inSDS-PAGE), accountedformainly
by one CII exon encoded peptide of 16 amino acids could not solely explain the
observed difference in molecularmass between the55-kD and40-kD non-disulfide-
linked TCRy surface forms. Form 2abc TCR-y polypeptides possess five potential
N-linkedglycan attachment sitesthat areprobablyall used, in contrast totheMOLT-13
TCR-y polypeptidewhich bears one additional potential attachment site, while car-
ryingonly two orthreeN-linked glycans. The reason for thislimited use ofpotential
attachment sites is unknown, but may result from the influence ofthe CII exon en-
coded peptides on the confirmation of the TCR-y protein. The CII exon-encoded
peptides and their neighbouring amino acids make up a connector region between
the plasma membrane and the Ig-like constant domain. This connector region con-
tains most of the N-linked glycan attachment sites (Fig. 5). We conclude that the
CII exon copies determine the protein form not only by determining polypeptide
backbone size, and by creating the ability to disulfide-link chains, but also by
influencing the amount of attached carbohydrates.
TCR8 cDNAs ofIDP2 (8), PEER (9), and MOLT-13 (40a) cells have been se-
quenced and were foundto beidentical, except for thediversity/Nregion interspacing
the variable and constant region gene segments. The TCRS protein on WM-13 cells
has a relative molecular mass of43 kD, which is similar to the TCR8 proteins de-
scribed by Borst et al. (16) and Lanier et al. (18), but is 3 kD larger than the otherHOCHSTENBACH ET AL.
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TCRS chains. These 43 kD TCRS proteins might indicate the presence of different
TCR-S variable domains.
Since structural differences comparable to thosedescribed for TCR-y constant re-
gion segments have not been observed for TCRa and TCR-(3 genes (41-44), the
significance of thedramatic structural diversity ofthesethree TCRy/S forms in man
remains a mystery. However, there is possible similarity in the number of human
CII exon repeats with the length in murine Cy regions, of which the Cyl, Cy2, and
Cy4 constant regions encode 15, 10, and 33 amino acid connector regions, respec-
tively (45, 46).
The ability to correlate protein size and presence or absence of disulfide linkage
with TCRy constant region gene structure allowed us to examine constant region
gene usage ofexpressed TCR-y/8 complexes in peripheral blood of healthy subjects.
Importantly, the human TCRy/S forms are not used equally. The mechanism(s)
responsible forthe unequalusage of the TCR-y/8 forms remains to be determined.
If selection does occur, it maybe at the level of theconstant region per se, or possibly
through the usage of J regions linked to these constant region gene segments. It
is also intriguing to consider the possibility that the structural diversity may prove
relevant to functional differences in these TCR-y/8 complexes.
Summary
A subpopulation of the CD3+ peripheral T lymphocytes express the TCRy/S
complex. Three distinct TCR-y forms that differ in size and in the ability to form
a disulfide bridge with the TCRS subunit have been described. In this study we
analyze the structural difference between the non-disulfide-linked 55-kD and 40-
kD TCR-y chains. The 40-kD TCRy form contains a smaller polypeptide back-
bone and carries less carbohydrate compared with the 55-kD TCRy form. AcDNA
clone corresponding to the 40-kD TCRy subunit lacks one copy of the second exon
of the constant region that is present in the other TCRy subunit. This exon copy
encodes part of the connector region that is located between the constant domain
andthemembrane spanning region. We show that the number ofpotential N-linked
glycan attachment sites are the same for the two TCRy forms. Since these attach-
ment sites are located in theconnector region we conclude that the connector region
influences the amount ofN-linked carbohydrates addedto the core TCRy polypep-
tide, probably by affectingthe conformation of the protein. In contrast to the TCR-
R constant region usage, the TCRy constant regions are unequally expressed. Vir-
tually exclusive usage of disulfide-linked complexes were found in some individuals,
while both the disulfide-linked and the 40-kD, non-disulfide-linked TCR-y forms
were detected in other subjects. The abilityto distinguish these TCR-y/8 forms now
makes it possible to study the mechanisms that govern their selection and to deter-
mine if they correspond to functionally distinct isotypes.
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